insights_auto
Why is DMN down 2,31%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,068 €
arrow_downward
-2,31%(-0,0016) 1D
10 նոյ, 22:00:00 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
147,08 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
147,08 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Yahoo Finance
·
15 րոպե առաջ
S&P 500 Sell-Off: 1 Investing Step to Take Right Now, and 1 Risky Move to Avoid
조선일보
·
1 ժամ առաջ
Anthropic Targets $1.4 Trillion Valuation in Nasdaq Listing
FXStreet
·
52 րոպե առաջ
Bitcoin leverage hits 99 percentile as Nasdaq correlation climbs
Bloomberg.com
·
4 ժամ առաջ
What to Know About the Anthropic IPO
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB